Objective: Our objective was to compare the sublingual administration and the vaginal administration of misoprostol for cervical priming before first-trimester surgical abortion.
Design: We used an open, multicenter, randomized trial.
Locations: We conducted the study in four clinics (in Valencia, Castelló, Murcia and Murcia Capital) in Spain.
Participants: A total of 1424 healthy pregnant women with amenorrhea of
Methods: Women were randomly assigned to receive a single dose of 400 microg of misoprostol either sublingually or vaginally 1-3 h before aspiration.
Outcome Measures: The outcome measures assessed were cervical dilation before surgery and surgical time needed for aspiration. The incidence of side effects, such as nausea, vomiting, diarrhea, fever/chills and paresthesia, was evaluated.
Results: The mean cervical dilation achieved was 6.8+/-0.8 and 6.7+/-0.9 mm for the sublingual and vaginal groups, respectively. The mean surgical time was 7.0+/-2.8 and 7.4+/-2.5 min for the sublingual and vaginal groups, respectively. Nausea, vomiting and diarrhea were more frequent in the sublingual group.
Conclusions: Both regimens had equal efficacy; however, the sublingual route caused more side effects.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.contraception.2006.03.031 | DOI Listing |
Nat Genet
January 2025
Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan.
Aberrant immune responses to viral pathogens contribute to pathogenesis, but our understanding of pathological immune responses caused by viruses within the human virome, especially at a population scale, remains limited. We analyzed whole-genome sequencing datasets of 6,321 Japanese individuals, including patients with autoimmune diseases (psoriasis vulgaris, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pulmonary alveolar proteinosis (PAP) or multiple sclerosis) and coronavirus disease 2019 (COVID-19), or healthy controls. We systematically quantified two constituents of the blood DNA virome, endogenous HHV-6 (eHHV-6) and anellovirus.
View Article and Find Full Text PDFCureus
January 2025
Biostatistics, All India Institute of Medical Sciences, New Delhi, New Delhi, IND.
The aim of the review was to systematically review real-world data on the effectiveness and safety of pembrolizumab in recurrent/metastatic/unresectable head and neck squamous cell cancer (HNSCC) patients. Two independent reviewers retrieved the studies separately and simultaneously. PubMed, Embase, Scopus, Web of Science, and Cochrane Central were searched for prospective and retrospective studies on recurrent/metastatic/unresectable HNSCC patients treated with either pembrolizumab monotherapy or pembrolizumab combination therapy published till November 2024.
View Article and Find Full Text PDFJ Neuroeng Rehabil
December 2024
Center for Healthcare Robotics, Korea Institute of Science and Technology, Seoul, 02792, Republic of Korea.
Introduction: Neck pain affects 203 million people globally and is prevalent in various settings due to factors like poor posture, lack of exercise, and occupational hazards. Therefore, addressing ergonomic issues with solutions like a wearable robotic device is crucial. This research presents a novel assistive exosuit, characterized by its slim and lightweight structure and intuitive control without the use of hands, designed to mitigate muscle fatigue in the neck and shoulders during prolonged flexed neck posture.
View Article and Find Full Text PDFbioRxiv
December 2024
Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Squamous cell carcinomas (SCC) are often preceded by potentially malignant precursor lesions, most of which remain benign. The terminal exhaustion phenotypes of effector T-cells and the accumulation of myeloid-derived suppressor cells (MDSC) have been thoroughly characterized in established SCC. However, it is unclear what precancerous lesions harbor a bona fide high risk for malignant transformation and how precancerous epithelial dysplasia drives the immune system to the point of no return.
View Article and Find Full Text PDFMenopause
December 2024
Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
Objectives: The aims of the study were to identify conditions diagnosed in at least 10% of midlife women living in the US upper midwest and to assess prevalence by age, race, ethnicity, and sociodemographic status.
Methods: The Rochester Epidemiology Project was used to conduct a cross-sectional prevalence study of 86,946 women between 40 and 59 years residing in a 27-county region of the United States on January 1, 2020. Diagnostic billing codes were extracted and grouped into broader condition categories using the Clinical Classification System Refined.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!